In conclusion, these findings highlight magnolol's ability to enhance the efficacy of RT in oral cancer by targeting the EGFR/NF‐κB axis, inducing apoptosis, and modulating immune responses, presenting a promising therapeutic strategy for OSCC. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.